Search research articles
Contact Us
Filters
Showing results (351-360 of 441) with videos related to
Page
of 45
Sort By:
Journal of Hepatology
|
November 24, 2022
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort
Alexandre Louvet, Valérie Bourcier, Isabelle Archambeaud, et al.
Gastroenterology
|
September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
Stefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology
|
January 22, 2014
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
Anna S Lok, David F Gardiner, Christophe Hézode, et al.
Gut
|
July 1, 2010
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
Bertrand Nalpas, Roubila Lavialle-Meziani, Sabine Plancoulaine, et al.
Kidney International
|
May 9, 2018
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective
Laurent Alric, Isabelle Ollivier-Hourmand, Emilie Bérard, et al.
Kidney International
|
September 24, 2018
Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management
Michel Jadoul, Marina C Berenguer, Wahid Doss, et al.
Hepatology (Baltimore, Md.)
|
February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection
David L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
JHEP Reports : Innovation in Hepatology
|
August 5, 2024
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
Selma El Messaoudi, Ségolène Brichler, Claire Fougerou-Leurent, et al.
Diabetes Care
|
April 12, 2023
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Laurent Castera, Cédric Laouenan, Anaïs Vallet-Pichard, et al.
The Journal of Experimental Medicine
|
June 25, 2020
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
Verena Hehle, Maxime Beretta, Maryline Bourgine, et al.
Page
of 45
Search research articles
Search
Showing results (351-360 of 441) with videos related to
Sort By:
Page
of 45
Journal of Hepatology
|
November 24, 2022
Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort
Alexandre Louvet, Valérie Bourcier, Isabelle Archambeaud, et al.
Gastroenterology
|
September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
Stefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Journal of Hepatology
|
January 22, 2014
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
Anna S Lok, David F Gardiner, Christophe Hézode, et al.
Gut
|
July 1, 2010
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection
Bertrand Nalpas, Roubila Lavialle-Meziani, Sabine Plancoulaine, et al.
Kidney International
|
May 9, 2018
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective
Laurent Alric, Isabelle Ollivier-Hourmand, Emilie Bérard, et al.
Kidney International
|
September 24, 2018
Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management
Michel Jadoul, Marina C Berenguer, Wahid Doss, et al.
Hepatology (Baltimore, Md.)
|
February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection
David L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
JHEP Reports : Innovation in Hepatology
|
August 5, 2024
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
Selma El Messaoudi, Ségolène Brichler, Claire Fougerou-Leurent, et al.
Diabetes Care
|
April 12, 2023
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
Laurent Castera, Cédric Laouenan, Anaïs Vallet-Pichard, et al.
The Journal of Experimental Medicine
|
June 25, 2020
Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
Verena Hehle, Maxime Beretta, Maryline Bourgine, et al.
Page
of 45